EXL Investor Presentation
Released
Released
Announcement PDF
ELIXINOL WELLNESS. (EXL)
Building the future of
everyday wellness
A strong foundation.
A clear market position.
A growing pipeline.
Coffee Microcaps Investor Presentation | 7 August 2026
INVESTOR PRESENTATION
The investment case is becoming simpler
The heavy lifting is largely behind us. The next phase is about building off that stable base into growth.
$4.3m
record Q2 FY26 revenue
45%
gross margin
vs 38% pcp
-23%
operating expenses
vs pcp
3 Quarters
positive underlying
operating cash flow
WHAT CHANGES THE EQUITY STORY
01 Quality of earnings
Margin and gross profit are growing
faster than sales.
02 Growth pathways
Priceline, grocery, ecommerce, B2B
and innovation & selective M&A.
03 Category tailwinds
Functional nutrition, healthy ageing
and metabolic health.
ELIXINOL WELLNESS | ASX: EXL 02
INVESTOR PRESENTATION
The business changed substantially over the past three years
That transformation accelerated in the last 12 months
EXL has moved from a legacy US Cannabis (CBD) story to an Australian health and wellness platform.
01
US CBD SCALE
A sizeable US CBD business
shaped the original investor
perception.
02
CATEGORY CONTRACTS
Post-COVID demand
softened as US regulation
became increasingly
uncertain.
03
AUSTRALIAN PLATFORM
BUILT
M&A brought together
trusted brands, channels
and local capability.
04
RESET, THEN GROW
Margin, costs and cash
discipline have been rebuilt.
The platform is ready to
scale again.
Legacy perceptions are outdated.
The earnings base is now increasingly Australian, diversified and growth-ready.
ELIXINOL WELLNESS | ASX: EXL 03
INVESTOR PRESENTATION
We Committed to a Reset. We Delivered the Transformation.
Clear commitments delivered, creating a stronger base for the next phase of growth.
✓ Stabilise the business
Capital management and liquidity reset completed.
✓ Improve unit economics
Gross margin reached 45%, up 3 percentage points on pcp.
✓ Reduce the cost base
Operating expenses reduced 23% on pcp.
✓ Establish cash discipline
Three consecutive quarters of positive underlying operating cash
flow.
✓ Reset obligations and ownership
THC earn-out restructured; Small Parcel Sale Facility completed.
→ Build new growth pathways
National retail expansion secured across Priceline, Coles and
Metcash, supported by an active innovation pipeline
The reset is substantially complete. The next proof point is disciplined growth.
ELIXINOL WELLNESS | ASX: EXL 04
INVESTOR PRESENTATION
Record revenue with gross margin expanding to 45%
$4.3m record Q2 FY26 revenue 45% gross margin, up from 38% pcp
Source: Elixinol Wellness Q2 FY26 Quarterly Activity Report and Appendix 4C, 28 July 2026.
ELIXINOL WELLNESS | ASX: EXL 04
INVESTOR PRESENTATION
A leaner cost base is translating into cash discipline
Operating expenses -23%
Employee costs -23%
Distribution -25%
Marketing -32%
Admin + corporate -15%
3
consecutive quarters
positive underlying
operating cash flow
Q2 FY26 underlying operating cash flow
+$0.05m
Reported Q2 cash flow included one-off AGM costs, interest and out-of-cycle
payments.
ELIXINOL WELLNESS | ASX: EXL 05
INVESTOR PRESENTATION
A Wellness Platform with Four brands, each with a clear purpose
THE HEALTHY CHEF
Women’s strength, vitality
and healthy ageing
MT ELEPHANT
Better-for-you indulgence
and family wellness
HEMP FOODS AUSTRALIA
Plant-based nutrition and
ingredient credibility
B2B INGREDIENTS
Nature-led innovation,
private label and B2B growth
ELIXINOL WELLNESS | ASX: EXL 06
B2B INGREDIENTS
Australia’s largest hemp foods company
A vertically integrated platform connecting contracted supply,
Australian processing and established retail relationships.
2 major grocery retailers supplied under
contracted arrangements with partners
2027 existing supply contracts extend to 2027
DEHULLING SEEDS + OIL PROTEIN PRIVATE LABEL
Scale and reliable supply create a defensible base for branded
products, private label and B2B ingredient growth.
ELIXINOL WELLNESS | ASX: EXL 07
INVESTOR PRESENTATION
The Healthy Chef is emerging as a core growth engine
$1.15m
Q2 FY26 revenue
27%
of Group revenue
+20%
revenue increase vs pcp
+26%
revenue increase vs Q1 FY26
Premium ecommerce base + pharmacy scale +
functional nutrition innovation
ELIXINOL WELLNESS | ASX: EXL 08
CHANNEL EXPANSION
Priceline puts The Healthy Chef in front of a national audience
~410
STORES
Stage 1 rollout
01 DISCOVERY Pharmacy visibility → 02 TRIAL Accessible entry
formats
→ 03 REPEAT Retail + ecommerce
ELIXINOL WELLNESS | ASX: EXL 09
INVESTOR PRESENTATION
A large part of the wellness market is shifting toward healthy ageing
US$6.8tn
global wellness economy in 2024
Projected to reach
US$9.8tn
by 2029
UP TO
60%
consider healthy ageing
a top or very important
priority
The opportunity sits where everyday nutrition meets strength, metabolism, sleep and long-term health.
Sources: Global Wellness Institute, 2025 Global Wellness Economy Monitor (Nov 2025); McKinsey & Company, Future of Wellness Trends Survey 2025 (May 2025).
ELIXINOL WELLNESS | ASX: EXL 10
INVESTOR PRESENTATION
GLP-1 awareness is creating a much wider “curious” market
GLOBAL WELLNESS CONSUMERS
Cleaner food, energy, strength and healthy ageing
GLP-1 CURIOUS
Everyday support for metabolism, satiety and protein intake
PEPTIDE CURIOUS
Interested in targeted nutrition without pharmaceutical involvement
ACTIVE CATEGORY USERS
Seeking practical support for appetite, muscle, recovery and
sleep
ELIXINOL WELLNESS | ASX: EXL 11
INNOVATION PLATFORM
The portfolio already has a credible entry point
01
PROTEIN WATERS
Lighter, convenient protein
→
02
METABOLIC BURN
Everyday metabolic support
→
03
NUTRITIONAL PEPTIDES
Sleep, muscle and expanded
weight management
NOW Existing products establish demand and permission. The pipeline expands into
adjacent, high-value needs.
ELIXINOL WELLNESS | ASX: EXL 12
INVESTOR PRESENTATION
EXL growth comes from four practical engines
01 PRODUCT INNOVATION
Build around protein, healthy ageing, convenience
and better-for-you indulgence.
02 CHANNEL EXPANSION
Scale through ecommerce, grocery, pharmacy,
health food and B2B.
03 OPERATING DISCIPLINE
Protect margin, share capability and allocate capital
carefully.
04 SELECTIVE ACQUISITION
Add aligned brands or capabilities that strengthen
the platform.
ELIXINOL WELLNESS | ASX: EXL 13
INVESTOR PRESENTATION
The next 6-12 months offer multiple proof points on execution
RETAIL Priceline rollout and broader pharmacy awareness
GROCERY Mt Elephant national expansion and new formats
INNOVATION Functional nutrition and nutritional or bioactive peptide pipeline
PORTFOLIO Continued mix improvement and B2B opportunities
CAPITAL Disciplined assessment of aligned acquisitions
ELIXINOL WELLNESS | ASX: EXL 14
INVESTOR PRESENTATION
Re-rating upside as market prices in revenue and earnings growth potential
EXL’s current valuation provides a low starting point as the Group moves from reset to growth.
A$2.9m
market capitalisation
Based on A$0.007 per share
and 413.99m shares on issue
6 AUGUST 2026
A$15.7m
L12M revenue
A$6.7m
L12M gross profit
0.18×
market cap / revenue
PATHWAY TO RECOGNITION
Consistent growth, sustained margins and continued
cash discipline can progressively reshape how the
market values EXL.
The disconnect is the opportunity: operating performance has changed, but the upside potential has not yet been priced in
L12M relates to last 12 months period ending 30 June 2026
ELIXINOL WELLNESS | ASX: EXL 16
ELIXINOL WELLNESS | ASX: EXL
A stronger foundation.
A clearer position.
A growing pipeline.
We are building a scalable wellness platform in categories
supported by long-term consumer demand.
LIVE WELL LIVE STRONG AGE BETTER
investorhub.elixinolwellness.com
Important Notice & Disclaimer
The following material is for general information purposes only and should not be relied on for the making of any investment decision. Any investment in
Elixinol Wellness Limited ACN 621 479 794 (Elixinol Wellness) is subject to a number of investment risks including the possibility of loss of capital invested and
no return of income or payment of dividends. Neither Elixinol Wellness nor any other entity or person in or associated with the Elixinol Wellness group of
companies guarantees any return (whether capital or income) or generally the performance of Elixinol Wellness or the price at which its securities may
trade.
In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Elixinol Wellness securities. This presentation is not
exhaustive of all of the information a potential investor, or their professional advisers would require. This presentation does NOT constitute a “Prospectus" or
a "Disclosure Document” (as defined in the Corporations Act 2001 (Cth) (Corporations Act)) and has not been, and will not be, lodged with the Australian
Securities and Investments Commission or any other regulatory authority. Accordingly, it is not required to contain, and may not necessarily contain, all of
the information that a Prospectus or like Disclosure Document would be required to contain pursuant to the Corporations Act.
This presentation does not take into account any specific objectives, financial situation or needs of investors. For these and other reasons, you are strongly
recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.
This presentation may contain "forward-looking statements" which are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”,
“anticipate(s)” and similar expressions are intended to identify forward-looking statements. Any forward-looking statements in this presentation should be
considered “at-risk statements” - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors that may lead to
actual results differing from any forward-looking statement. You are cautioned not to place undue reliance on these forward-looking statements that speak
only as of the date hereof and Elixinol Wellness does not undertake any obligation to revise and disseminate forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events. In addition, the past performance of Elixinol Wellness
cannot be assumed as indicative of the future performance. There is NO guarantee of future performance - actual results and future outcomes will in all
likelihood differ from those outlined in this Presentation.
Neither Elixinol Wellness nor any of its advisers, agents or employees make or give any express or implied representation, warranty or guarantee that the
information contained in this presentation or otherwise supplied by or on behalf of Elixinol Wellness is complete or accurate or that it has been or will be
audited or independently verified, or that reasonable care has been or will be taken in compiling, preparing or furnishing the relevant information. Elixinol
does not take any responsibility for any inference, interpretation, opinion or conclusion that any person may draw or form from this presentation.
To the maximum extent permitted at law, Elixinol Wellness and all of its representatives, directors, partners, employees or professional advisers exclude all
direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other
than to the extent required by law (and only to that extent), they do not make any representation or give any assurance, guarantee or warranty (express or
implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or
omissions from, any information, statement or opinion contained in this Presentation or any accompanying, previous or subsequent material or
presentation.
This Presentation is current as at 7 August 2026
ELIXINOL WELLNESS | ASX: EXL 12
Share your feedback
Discover